Amyloid inhibitors and Alzheimer's disease

Current Opinion in Investigational Drugs

Volumn 4, Issue 1, 2003, Pages 55-59

  Xia, Weiming ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

secretase; Amyloid; BACE; NSAID; Presenilin; Statin; Vaccination

Indexed keywords

1 [6 (2 CARBOXYPYRROLIDIN 1 YL) 6 OXOHEXANOYL]PYRROLIDINE 2 CARBOXYLIC ACID; ALPHA SECRETASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID INHIBITOR; ATORVASTATIN; BENZENE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA SECRETASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CLIOQUINOL; CONJUGATED ESTROGEN; FENCHYLAMINE SULFONAMIDE INHIBITOR; FLURBIPROFEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; ISOCOUMARIN DERIVATIVE; L 685458; NAPROXEN; NCX 2216; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RO 63 8695; ROFECOXIB; ROSIGLITAZONE; SULINDAC SULFIDE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; NEUROTOXICITY; NONHUMAN; PAIN; PATHOGENESIS; POSTVACCINAL ENCEPHALITIS; PROTEIN AGGREGATION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIDE EFFECT; VACCINATION; VITAMIN SUPPLEMENTATION;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTIC ENDOPEPTIDASES; ENDOPEPTIDASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SENILE PLAQUES; VACCINATION;

EID: 0037286719     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science (2002) 297(5580):353-356. Presents the amyloid hypothesis, which is the theoretical basis for amyloid therapeutics.
2. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y et al: β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 286(5440):735-741. Cloning of βsecretase provided of the most promising therapeutic targets for the treatment of AD (see also references [3] and [4]).
3. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K et al: Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature (1999) 402(6761):537-540. Cloning of β-secretase provided one of the most promising therapeutic targets for the treatment of AD (see also references [2] and [4]).
4. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB et al: Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature (1999) 402(6761):533-537. Cloning of β-secretase provided one of the most promising therapeutic targets for the treatment of AD (see also references [2] and [3]).
5. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC: BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat Neurosci (2001) 4(3):233-234. Almost no Aβ synthesis was detected in BACE1 knockout mice, indicating that BACE1 is the major β-secretase and its inhibitor should block Aβ production.
6. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L et al: Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci (2001) 4(3):231-232. The normal phenotype of BACE1 knockout mice suggests that BACE-1 inhibitors should not cause major side effects in therapeutic applications.
7. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J: Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science (2000) 290(5489):150-153.
8. Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H: Substrate and inhibitor profile of BACE (β-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem (2002) 277(7):4687-4693.
9. Rishton GM, Retz DM, Tempest PA, Novotny J, Kahn S, Treanor JJ, Lile JD, Citron M: Fenchylamine sulfonamide inhibitors of amyloid β peptide production by the γ-secretase proteolytic pathway: Potential small-molecule therapeutic agents for the treatment of Alzheimer's disease. J Med Chem (2000) 43(12):2297-2299.
10. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE Jr, Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN et al: Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors. J Biol Chem (2000) 275(44):34086-34091.
11. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G, Castro JL: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry (2000) 39(30):8698-8704.
12. Li Y-M, Xu M, Lai M-T, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelli JG, Register RB et al: Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature (2000) 405(6787):689-694. This study suggets that presenilin may contain the active site of γ-secretase.
13. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature (1999) 398(6727):513-517.
14. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, Tsai JY, Rahmati T, Xia W, Selkoe DJ, Wolfe MS: Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat Cell Biol (2000) 2(7):428-434.
15. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, Wolfe MS: Activity-dependent isolation of the presenilin-γ-secretase complex reveals nicastrin and a γ substrate. Proc Natl Acad Sci USA (2002) 99(5):2720-2755.
16. Petit A, Bihel F, Alves Da Costa C, Pourquie O, Checler F, Kraus JL: New protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting Notch cleavage. Nat Cell Biol (2001) 3(5):507-511.
17. Esler WP, Das C, Campbell WA, Kimberly WT, Kornilova AY, Diehl TS, Ye W, Ostaszewski BL, Xia W, Selkoe DJ, Wolfe MS: Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase. Nat Cell Biol (2002) 4(5):E110-E111.
18. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohanan D, Keller P, Runz H, Kuhl S, Bertsch T, Von Bergmann K, Hennerici M et al: Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA (2001) 98(10):5856-5861.
19. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol (2000) 57(10):1439-1443.
20. Green RC, McNagny SE, Jayakumar P, Cupples LA, Benke K, Farrer L: Statin use is associated with reduced risk of Alzheimer's disease. Neurobiol Aging (2002) 23(S273):Abs 1025.
21. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM: Acyl-coenzyme A: Cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nat Cell Biol (2001) 3(10):905-912.
22. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F et al: Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat Med (1998) 4(4):447-451.
23. Greenfield JP, Leung LW, Cai D, Kaasik K, Gross RS, Rodriguez-Boulan E, Greengard P, Xu H: Estrogen lowers Alzheimer β-amyloid generation by stimulating trans-golgi network vesicle biogenesis. J Biol Chem (2002) 277(14):12128-12136.
24. Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. J Am Med Assoc (2002) 288(3):321-333.
25. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE et al: A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature (2001) 414(6860):212-216.
26. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 416(6880):535-539.
27. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ: Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci (1999) 19(20):8876-8884.
28. 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA (1998) 95(11):6448-6453.
29. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X et al: Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 30(3):665-676.
30. 12 and trace metals in brains of mice treated with clioquinol. J Neurol Sci (2000) 173(1):40-44.
31. Lowe TL, Strzelec A, Kiessling LL, Murphy RM: Structure-function relationships for inhibitors of β-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry (2001) 40(26):7882-7889.
32. Gordon DJ, Sciarretta KL, Meredith SC: Inhibition of β-amyloid(40) fibrillogenesis and disassembly of β-amyloid 40 fibrils by short β-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry (2001) 40(28):8237-8245.
33. Castillo GM, Lukito W, Peskind E, Raskind M, Kirschner DA, Yee AG, Snow AD: Laminin inhibition of β-amyloid protein (Aβ) fibrillogenesis and identification of an Aβ binding site localized to the globular domain repeats on the laminin a chain. J Neurosci Res (2000) 62(3):451-462.
34. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T et al: Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 417(6886):254-259.
35. Skovronsky DM, Zhang B, Kung MP, Kung HF, Trojanowski JQ, Lee VM: In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA (2000) 97(13):7609-7614.
36. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN: Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 22(6):2246-2254.
37. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE: Inflammatory mechanisms in Alzheimer's disease: Inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci (2000) 20(2):558-567.
38. Niino M, Iwabuchi K, Kikuchi S, Ato M, Morohashi T, Ogata A, Tashiro K, Onoe K: Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-γ. J Neuroimmunol (2001) 116(1):40-48.
39. Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med (2000) 6(12):1399-1402.
40. 2+ deregulation, and cytoskeletal pathology. Neurobiol Aging (1995) 16(2):187-198.
41. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DL, Reiter RJ, Efthimiopoulos S, Robakis NK: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci (1997) 17(5):1683-1690.
42. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D et al: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400(6740):173-177.
43. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K et al: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408(6815):982-985.
44. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT et al: Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408(6815):979-982.
45. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, Von Rotz RC, Davey G, Mortiz E, Nitsch RM: Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat Med (2002) 8(11):1270-1275.
46. Check E: Nerve inflammation halts trial for Alzheimer's drug. Nature (2002) 415(6871):462.
47. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C et al: Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med (2002) 8(11):1263-1269.
48. Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, Hancock WW, Weiner HL, Selkoe DJ: Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann NY Acad Sci (2000) 920:328-331.
49. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ: Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol (2000) 48(4):567-579.
50. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Kahn K et al: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 6(8):916-919.
51. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA (2001) 98(15):8850-8855.
52. Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, Tolnay M, Staufenbiel M, Jucker M: Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci (2001) 21(5):1619-1627.
53. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M: Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science (2002) 298(5597):1379.